Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysisHuseyin Naci, Christopher M. Booth, Jelena Savović et al.|BMJ|2019Cited by 242
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United StatesMaximilian Salcher‐Konrad, Courtney Davis|Milbank Quarterly|2020Cited by 87